combined BRAF-MEK inhibitors

Encorafenib plus binimetinib - Vemurafenib and cobimetinib      

pathologytreatmentpatient Demonstrated benefit and harm k      
melanomaencorafenib plus binimetinib1L

versus

No demonstrated result for efficacy

1 trialmeta-analysis
melanomatrametinib + dabrafenib not classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
melanomatrametinib + dabrafenib 1L

versus

No demonstrated result for efficacy

1 trialmeta-analysis
melanomatrametinib + dabrafenib 1L unresectable

versus

No demonstrated result for efficacy

1 trialmeta-analysis
melanomatrametinib + dabrafenib adjuvant

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
melanomavemurafenib and cobimetinibnot classified

versus 1L unresectable

No demonstrated result for efficacy

1 trialmeta-analysis